We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

tn bionano webinar 2nd May 2024

Assess Genomic Integrity With Optical Genome Mapping

Cell and gene therapies (CGT) mark a transformative phase in medical innovation, with the FDA endorsing 32 treatments by 2023 and over 1,000 CGTs currently in U.S. clinical trials, alongside 3,000 in preclinical phases. While these therapies hold immense potential in disease management, ensuring their integrity is crucial. Challenges like mutations from genetic editing and extended culture growth pose risks to CGTs' safety and efficacy. Conventional genomic analysis methods often fall short in detecting critical structural variants. In this webinar, you’ll discover how to evaluate cell and gene therapy genetic integrity and purity with optical genome mapping (OGM). 


Attend this webinar to:

  • Explore the evolving landscape of CGT and the imperative of ensuring therapeutic safety
  • Gain an introduction to OGM's capabilities in assessing genomic integrity
  • Hear how OGM can be applied at various stages of CGT development
  • Learn from insightful case studies showcasing OGM's impact in CGT research and development

Speakers
Owen Pearce
Owen Pearce
Senior Research Associate
eGenesis
Dr. Michael Gallagher
Dr. Michael Gallagher
Market Development Manager
Bionano
Brought to you by
Now Available on Demand!
Information you provide will be shared with the sponsors for this content. Technology Networks or its sponsors may contact you to offer you content or products based on your interest in this topic. You may opt-out at any time.
Want to invite a colleague?

Click the button below to begin inviting a colleague to this Webinar